Celsius Shares Fall as Second-Quarter Sales Miss Expectations
Energy drink maker Celsius Holdings Inc. saw its stock decline after second-quarter sales fell short of expectations and sales of its namesake brand dropped. The company's financial results heightened investor concerns about sales growth and put pressure on the stock.
Celsius's second-quarter revenue lagged market analysts' forecasts. The decline in sales of the company's flagship Celsius-branded drinks stood out as the main reason for the weakness in total revenue. This was interpreted as a sign that the company's growth momentum is slowing.
Investors believe that intensifying competition in the energy drink sector and fluctuations in consumer demand have negatively impacted Celsius's sales performance. With second-quarter results coming in below market expectations, the drop in the stock price reflects a weakening in investor confidence.
Although Celsius Holdings has signaled that it may take strategic steps to revive sales in the coming period, the current picture increases uncertainties about the company's short-term outlook. Market analysts say that the company's third-quarter performance will be decisive in determining whether its growth story continues.
This is not investment advice.
📊 CELH — Piyasa Yorumu
▼ down · 65%The headline indicates that Celsius's second-quarter sales fell short of expectations, leading to a decline in the stock. This could create negative sentiment in the short term and increase selling pressure. While technical indicators present a neutral outlook (RSI at 49, price near SMA20 and SMA50), the MACD is just below the signal line and momentum is weak. The news may prompt the price to test current support levels, but the downside is expected to be limited as the sell-off may already be priced in. Overall, a downward movement is anticipated in the short term.
RSI 14
49.1
MACD
0.17
24h Δ
0.66%
Canlı Grafikler
🔗 İlgili haberler
⭐ 67 · 45 dk önce
Celsius Holdings Q2 2026'da Beklentileri Karşılayamadı, Marka Satışları Düştü
⭐ 76 · 14.07
FDA, Celcuity'nin Meme Kanseri İlacına Onay Verdi
⭐ 63 · 14.07
FDA, Celcuity'nin Meme Kanseri İlacına Onay Verdi
⭐ 67 · 17.06
Bernstein, Celsius Holdings İçin 'Endeksin Üzerinde Getiri' Tavsiyesi Verdi
⭐ 67 · 02.06
Celcuity Hisseleri Meme Kanseri Deneyinde Hayal Kırıklığıyla Düştü
⭐ 68 · 12.05
JPMorgan, Celanese hissesi için notunu yükseltti: Değerleme ve nakit akışı vurgusu
🧬 Buna benzer
⭐ 67
Cybertruck 'Otomotiv Tarihinin En Büyük Fiyaskosu' Olarak Nitelendirildi, Tesla Hisseleri Düşüşte
⭐ 67
PepsiCo 2. Çeyrek 2026: Gelir Beklentiyi Aştı, Hisse Başı Kâr Kaçırdı, ABD'de Durgunluk
⭐ 67
Ciena hisseleri düşüşte, diğer optik ağ hisselerini de beraberinde sürüklüyor
⭐ 65
First Brands İflasında Dolandırıcılık Davalarıyla 2 Milyar Dolar Geri Kazanım Hedefi
AI tarafından yeniden derlenmiştir. Yatırım tavsiyesi değildir.